First-in-Human Evaluation of the Safety and Immunogenicity of a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine (IPCAVD 001)Lindsey R. Baden, Dan H. Barouch, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2012Cited by 168
Characterization of Humoral and Cellular Immune Responses Elicited by a Recombinant Adenovirus Serotype 26 HIV-1 Env Vaccine in Healthy Adults (IPCAVD 001)Dan H. Barouch, Lindsey R. Baden, Jinyan Liu et al.|The Journal of Infectious Diseases|2012Cited by 107
First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara VectorLindsey R. Baden, Kelly Stanley, Stephen R. Walsh et al.|The Journal of Infectious Diseases|2018Cited by 45
962 A novel alpha-active IL-2-Fc has expanded therapeutic index and robust monotherapy efficacy in mouse cancer models and strong synergy with PD-1 blockadeAdam Stockmann, Ann Cheung, S.R. Vincent et al.|Regular and Young Investigator Award Abstracts|2024Cited by 0
DF6215, an α-optimized IL-2-Fc fusion, expands immune effectors and drives robust preclinical anti-tumor activityAdam Stockmann, Ann Cheung, Nicolai Wagtmann et al.|Cell Reports Medicine|2025Cited by 0